日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

The European Medicines Agency Review of Gilteritinib (Xospata) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an FLT3 Mutation

欧洲药品管理局对吉瑞替尼(Xospata)用于治疗伴有FLT3突变的复发或难治性急性髓系白血病成人患者的审查

Tzogani, Kyriaki; Røshol, Hilde; Olsen, Helga Haugom; Aas, Ida B; Dalhus, Marianne Løiten; Håkonsen, Gro Dahlseng; Nilssen, Laila Sortvik; Lindberg, Vibeke; Økvist, Mats; Bolstad, Bjørg; Rogovska, Irēna; Karpova, Natalja; Enzmann, Harald; Gisselbrecht, Christian; Pignatti, Francesco